COVID-19 in adult acute myeloid leukemia patients a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) /
Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and Octobe...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | HAEMATOLOGICA
108 No. 1 |
| Tárgyszavak: | |
| doi: | 10.3324/haematol.2022.280847 |
| mtmt: | 33709057 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/26780 |
| LEADER | 02905nab a2200397 i 4500 | ||
|---|---|---|---|
| 001 | publ26780 | ||
| 005 | 20230322121013.0 | ||
| 008 | 230322s2023 hu o 0|| Angol d | ||
| 022 | |a 0390-6078 | ||
| 024 | 7 | |a 10.3324/haematol.2022.280847 |2 doi | |
| 024 | 7 | |a 33709057 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Marchesi Francesco | |
| 245 | 1 | 0 | |a COVID-19 in adult acute myeloid leukemia patients |h [elektronikus dokumentum] : |b a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) / |c Marchesi Francesco |
| 260 | |c 2023 | ||
| 300 | |a 22-33 | ||
| 490 | 0 | |a HAEMATOLOGICA |v 108 No. 1 | |
| 520 | 3 | |a Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 2 | |a Salmanton-García Jon |e aut |
| 700 | 0 | 2 | |a Emarah Ziad |e aut |
| 700 | 0 | 2 | |a Piukovics Klára |e aut |
| 700 | 0 | 2 | |a Nucci Marcio |e aut |
| 700 | 0 | 2 | |a Nucci Marcio |e aut |
| 700 | 0 | 2 | |a López-García Alberto |e aut |
| 700 | 0 | 2 | |a Ráčil Zdeněk |e aut |
| 700 | 0 | 2 | |a Farina Francesca |e aut |
| 700 | 0 | 2 | |a Popova Marina |e aut |
| 700 | 0 | 2 | |a Zompi Sofia |e aut |
| 700 | 0 | 2 | |a Audisio Ernesta |e aut |
| 700 | 0 | 2 | |a Ledoux Marie-Pierre |e aut |
| 700 | 0 | 2 | |a Verga Luisa |e aut |
| 700 | 0 | 2 | |a et al. |e aut |
| 700 | 0 | 2 | |a Kollaborációs szervezet: EPICOVIDEHA working group |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/26780/1/marchesi.pdf |z Dokumentum-elérés |